[E-Daily Reporter Kwon Oh Seok ] Hana Securities announced on the 15th that it is maintaining its “Buy” investment rating and target price of 140,000 won for LG Corp.(003550).

Choi Jeong-wook, an analyst at Hana Securities, noted that LG AI Research held the “LG AI Talk Concert 2026” at the LG Corp. Science Park in Magok, Seoul, the previous day (the 14th), and commented, “They unveiled their ‘Expert AI’ strategy for solving challenges in industrial settings, along with key achievements.”
He explained, “‘EXAONE,’ developed by LG Corp.’s AI Research division, stands for ‘Expert AI for Everyone.’ The goal is not merely to create high-performance general-purpose AI, but to solve real-world problems in industries such as manufacturing, science, healthcare, and finance, thereby leading to tangible business outcomes such as cost savings and improvements in productivity and quality.”
To date, it has solved over 100 real-world industrial problems and expanded its portfolio of domain-specific models, including “EXAONE Tabular” for analyzing structured data, the vision inspection model “EXAONE Only Inspect,” “EXAONE Discovery” for material exploration, the pathology analysis model “EXAONE Path,” and the time-series forecasting model “EXAONE Forecast.”
Researcher Choi said, “We plan to expand AI capabilities to the point where it can make decisions and take action directly on the shop floor through ‘EXAONE Data Foundry’—which develops specialized AI using internal corporate data—as well as Agent AI that independently defines, plans, and executes tasks; an autonomous AI laboratory that conducts 24-hour cycles of experimentation and learning; and robot foundation models.”
He added, “In the case of EXAONE Tabular, we’ve seen significant demand not only from affiliates such as LG Innotek but also from overseas pharmaceutical companies, hospitals, and energy firms, starting with its implementation at these affiliates. We are expanding its applicability to various fields, such as predicting vital signs in intensive care units and analyzing pharmaceutical production data.” He emphasized, “In particular, we have made it clear that we are willing to provide this technology even to competitors like SamsungElectronics if needed, and we are open to collaboration that enhances the AI competitiveness of the entire domestic industry.” “Therefore, we expect to be able to recognize external revenue and achieve monetization in the near future,” he said.